Community Research and Development Information Service - CORDIS

ERC

BeyOND Report Summary

Project ID: 335692
Funded under: FP7-IDEAS-ERC
Country: Germany

Mid-Term Report Summary - BEYOND (METABOLIC BASIS OF NEURODEGENERATIVE DISEASE)

Age-related dementias, such as Alzheimer’s disease (AD), represent a major burden to affected patients and their families. Disturbingly, common disorders of the metabolism, including obesity and diabetes emerge as major risk factors for individuals to succumb to AD. Thus, an ever increasing life expectancy combined with an observable rise in metabolic diseases in developed and in developing countries is expected to turn AD into one of the most serious health problems worldwide. Still, the disease mechanisms, whereby changes in whole body metabolism promote neurodegeneration, remain poorly understood. In BeyOND, neuroscientists and metabolism researchers collaborate with clinicians to elucidate disease mechanisms linking metabolism and dementia, and to develop novel therapeutic concepts for treatment of AD. In the current reporting period (February 2014 - July 2016), scientists in BeyOND have made major progress towards these ambitious goals identifying altered activity of the receptor SORLA as the common cause of diet-induced obesity and neurodegeneration in transgenic mouse models and in patients. Furthermore, they uncovered the receptor sortilin as a major player in control of lipid transport processes predictive of AD risk, and they characterized two receptors SORCS1 and SORCS3 in nerve cells that cooperate to control the levels of neurotoxic protein fragments (so called amyloid peptides) in the brain.

Contact

Ioannis Legouras, (EU Liaison Officer)
Tel.: +49 30 9406 4247
Fax: +49 30 9406 2681
E-mail
Record Number: 189615 / Last updated on: 2016-10-12